Pfizer’s coronavirus vaccine test results and 1.2 billion vaccine goal

Pfizer and German partner BioNTech have released info on their coronavirus vaccine tests. They expain the good news and announce new goals for distribution.
Patient receiving a vaccine.

American pharmaceutical company Pfizer and German partner BioNTech have released their coronavirus vaccine’s test results. Along with this, they’ve announced a 1.2 billion manufacturing expectation to be met by the end of 2021.

Pfizer’s coronavirus vaccine

Pfizer reported their Phase 1/2 testing results on Wednesday. They are published on MedRXiv. The stages of vaccine development typically go through phases. There are usually 3. Each phase introduces more volunteers to the study.

Pfizer is developing four vaccines. This one, named BNT162b2, is the most advanced and effective.

The participants were all between the ages of 18 and 25. No pregnant women were involved. Statistics on diversity aren’t a part of the results but the reports say Phase 3 should be more diverse.

The Phase 1/2 trials consisted of 45 participants. Different doses were tested, ranging from low, medium, and high. These doses consisted of 10-micrograms, 30-micrograms, and 100-micrograms, respectively. Two injections of each dose were given. They were a month apart. Antibodies that fight the virus were apparent after 28 days. The levels of neutralizing antibodies were 1.8-2.8 times higher than those found in recovered coronavirus patients.

Side effects were typical: arm pain at the injection site, a fever, and sleep disturbances. The percentage of people experiencing side effects went up with the dosage level. However, those who received the highest dose only had more side effects and weren’t positively affected in terms of fighting the virus. More than 50% of volunteers reported some form of side effect. There were no hospitalizations, cause of disability, or life-threatening reactions.

What’s next

Pfizer is aiming to launch large-scale tests by Fall. It will consist of about 30,000 volunteers. They are going to be conducted in the United States. They will be conducting final phase testing alongside Oxford (with partner AstraZeneca) and CanSino Biologics.

Theyre expecting 100 million doses of this vaccines by the end of 2020. They are also expecting 1.2 billion by the end of 2021.